BRAHMS, Cezanne and Lumiphore Announce Partnership for Diagnostic Tests

BERLIN, NIMES, France and RICHMOND, California - Diagnostics company BRAHMS Aktiengesellschaft, Cezanne and Lumiphore Inc., a biotechnology leader from California, announced that they have signed an agreement on incorporation of Lumiphore’s Lumi4(R)-Tb complexes in BRAHMS diagnostic tests.

Under the agreement, BRAHMS together with its subsidiary Cezanne, developer and manufacturer of KRYPTOR automated diagnostic solutions, has the non-exclusive rights to incorporate Lumi4(R) technology into current and future diagnostic tests and the exclusive rights to use the technology in diagnostic tests for Down’s Syndrome including Trisomy 21, 13 and 18, Triploidy, Translocation, and Mosaicism.

“Lumiphore’s goal is to bring the benefits of lanthanide-based homogenous assays to the diagnostic markets, from central labs to point-of-care applications. Detection sensitivity and simplicity of use as well as material cost reductions in reagent use, labor, and reader platforms are all benefits of Lumiphore’s new reporter technology,” said Steve Blose Lumiphore’s Chief Business Officer.

“Using Lumi4(R)-Tb in the reader technology of our diagnostic tests will provide multiple benefit for BRAHMS. Thus we will take Lumi4(R)-Tb into consideration for the development of future analysis systems, both in laboratories and point-of-care-formats,” said Ansgar Schmitt, BRAHMS’ Vice President Business Development.

Lumi4(R)-Tb will both increase sensitivity of BRAHMS diagnostic tests and allow the development of multiplexed assays (measuring 3-4 parameters in one test sample).

About BRAHMS Aktiengesellschaft

The BRAHMS AG conducts researches, develops, produces and markets innovative diagnostic biomarkers. The company sells its products in more than 65 countries via its own subsidiary companies and sales organizations as well as laboratory systems from its own production and globally operating licensees.

About Lumiphore, Inc.

Based in Richmond, California, Lumiphore Inc, a privately held company, is a biotechnology leader in the development of proprietary fluorescent-metal lanthanide technology for use in high-value applications which are commercialized through market-specific alliances with corporate partners. Lumi4(R) complexes are a new class of fluorescent-metal lanthanide detection reagents based on technology patented by Professor Kenneth N. Raymond and coworkers at the University of California, Berkeley. Lumi4(R) is a registered mark of Lumiphore, Inc.

Media Contact BRAHMS Aktiengesellschaft Ingo Buchholzer Public Relations Manager +49-3302-883-637 i.buchholzer@brahms.de www.brahms.de Lumiphore, Inc. Stephen Blose Chief Business Officer +1-415-318-4457 mvsgroup@msn.com www.lumiphore.com Cezanne,SAS Emmanuel Bois President +33-466-365-236 ebois@cezanne.fr www.cezanne.fr

Source: BRAHMS Aktiengesellschaft

Media Contact: BRAHMS Aktiengesellschaft, Ingo Buchholzer, Public Relations Manager, +49-3302-883-637, i.buchholzer at brahms.de, https://www.brahms.de. Lumiphore, Inc., Stephen Blose, Chief Business Officer, +1-415-318-4457, mvsgroup at msn.com, https://www.lumiphore.com. Cezanne,SAS, Emmanuel Bois, President, +33-466-365-236, ebois at cezanne.fr, https://www.cezanne.fr